1BAKER BF, MONIA BP. Novel mechanisms for antisense-midiated regulation of gene expression [ J ]. Biochemica et Biophysica Acta, 1999,1489(1) :3-18.
2WERNER M, ROSA E, NORDSTROM JL, et al. Short oligonucleotidea as external guide sequences for site-specific cleavage of RNA molecules with human RNase P[J]. RNA, 1998,4(7) :847-855.
3MA M, BENIMETSKAYA L, LEBEDEVA l, et al. Intracallular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences[ J ]. Nat Biotech, 2000,18(1):58-61.
4WU HJ, MACLEOD AR, LIMA WF, et al. Indentification and partial purification of human double strand RNase activity[ J ]. J Biol Chem, 1998,273(5) :2532-2542.
5TORRENCE PF, XIAO W, LI G, et al. Recruiting the 2-5A system for antisense therapeutics [ J ]. Antisense Nucleic Acid Drug Dev, 1997,7(3) :203-206.
6XIAO W, LI G, PLAYER MR, et al. Nuclease-resistant composite 2', 5'-oligoadenylate-3', 5'-oligonucleotides for the targeted destruction of RNA: 2-5A-iso-antisense[J ]. J Med Chem, 1998,41 (9) : 1531-1539.
7KOGA S, KONDO Y,KOMATA T,et al. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA[J]. Gene Ther, 2001, (8) :654-658.
8MUKAI S, KONDO Y, KOGA S,et al. 2-5 A antisense telomerase RNA therapy for intracranial malignant gliomas[J ]. Cancer Res,2000,60(16) :4461-4467.
9KONDO Y, KOGA S, KOMATA T, et al. Treatment of prostate cancer in vitro and in vivo with 2-5 A-anti-telomerase RNA component [ J ]. Oncogene, 2000,19 (18) : 2205-2211.
10BAKER BF, LOT SS, CONDON TP, et al. 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1)oligonueleotides selectively increase the ICAM-1 mRNA level andinhibit for mation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells [ J ]. J Biol Chem, 1997,272(18) : 1994-2000.
